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Abstract
Hyperthermia enhanced transdermal (HET) immunization is a novel needle free immunization strategy employing
application of antigen along with mild local hyperthermia (42uC) to intact skin resulting in detectable antigen specific Ig in
serum. In the present study, we investigated the adjuvant effect of thermal component of HET immunization in terms of
maturation of dendritic cells and its implication on the quality of the immune outcome in terms of antibody production
upon HET immunization with tetanus toxoid (TT). We have shown that in vitro hyperthermia exposure at 42uC for
30 minutes up regulates the surface expression of maturation markers on bone marrow derived DCs. This observation
correlated in vivo with an increased and accelerated expression of maturation markers on DCs in the draining lymph node
upon HET immunization in mice. This effect was found to be independent of the antigen delivered and depends only on the
thermal component of HET immunization. In vitro hyperthermia also led to enhanced capacity to stimulate CD4+ T cells in
allo MLR and promotes the secretion of IL-10 by BMDCs, suggesting a potential for Th2 skewing of T cell response. HET
immunization also induced a systemic T cell response to TT, as suggested by proliferation of splenocytes from immunized
animal upon in vitro stimulation by TT. Exposure to heat during primary immunization led to generation of mainly IgG class
of antibodies upon boosting, similar to the use of conventional alum adjuvant, thus highlighting the adjuvant potential of
heat during HET immunization. Lastly, we have shown that mice immunized by tetanus toxoid using HET route exhibited
protection against challenge with a lethal dose of tetanus toxin. Thus, in addition to being a painless, needle free delivery
system it also has an immune modulatory potential.
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Introduction
Needle-free devices for transdermal immunization can make
vaccination painless, safe and affordable [1]. Several technologies
including iontophoresis [2], sonophoresis [3,4] microneedle
delivery [5,6] chemical permeation enhancement [7,8] and
particles or jet injection [9,10] are being explored for this purpose.
We have been investigating the hyperthermia enhanced transder-
mal (HET) immunization as a novel, without-needle immunization
technology which is comparatively easy to generate and puts less
strain on the recipient [11]. Febrile range mild hyperthermia is
known to modulate the activation and maturation of dendritic cells
both in vitro and in vivo [12–14] Use of hyperthermia in cancer
vaccination has already been investigated and is being developed
for stimulation of tumor-antigen bearing dendritic cells during
adoptive transfer [15,16].
The dendritic cells (DCs) are antigen presenting cells which are
present in small number in tissues which are in contact with the
external environment, mainly the skin, the inner lining of the nose,
lungs, stomach, and intestine. They ingest antigens in peripheral
tissues, migrate to lymph nodes and present MHCII bound
antigen to CD4 T cells, which forms the basis of T cell immunity
against bacterial antigens. The DCs are the most efficient antigen
presenting cells as they have remarkable migratory capacity,
optimal efficiency to capture and process antigens, and high level
expression of MHC complex as well as co-stimulatory and
adhesion molecules. The intricate pathways followed by DCs in
these processes have been highlighted by some authors [17,18].
Dermal dendritic cells and Langerhans cells are an important
class of antigen presenting cells in the skin. The epidermal
dendritic cells, upon encountering the antigen in periphery, are
known to undergo maturation and migrate out of skin to the
lymph node, where they present the antigens to T cells [19].
Various physical and chemical stimulants like LPS are known to
cause the change in the co-stimulatory profile of DCs, thus
affecting their antigen presenting capacity [20]. The cytokines
secreted by DCs upon activation are known to influence the Th1/
Th2 balance, in turn regulating the immune outcome in terms of
the class of antibodies generated [21].
Here, we have investigated how the thermal component of this
novel immunization technique influences the phenotype and
functions of DCs in vivo and in vitro. We also examined the
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skews the Th response, which in turn determines the antibody
response generated in vivo. Also, we have shown that HET
immunization generates protective immunity to toxin mediated
paralysis and death. Thus, the current study establishes that
besides being a non-invasive and painless method of immuniza-
tion, HET immunization also have adjuvant properties, is able to
skew the immune outcome in terms of antibody generation and T
helper response, and provides protective immunity as well.
Results
In vitro hyperthermia up regulates the expression of
activation markers on dendritic cells
To study the effect of hyperthermia on activation of dendritic
cells, BMDCs from day 7 of bone marrow culture were harvested
and plated at a concentration of 1 million cells/ml in a 6- well
plate. Immature as well as LPS (1 mg/ml; 6 hours) matured
BMDCs were given in vitro hyperthermia (42uC for 30 minutes)
followed by recovery at 37uC for indicated durations and the
expression of activation markers CD80, CD86, MHCII and CD40
was assessed by flow cytometry. The recovery period was chosen
on the basis of kinetics of expression of individual marker (data not
shown). As shown in Figure 1, in vitro hyperthermia followed by
recovery at 37uC caused up regulation of co-stimulatory molecules
CD80 and CD86, antigen presentation marker MHCII as well as
DC maturation marker CD40. Although the expression of CD80
was distinct, the expression of CD86, CD40, and MHCII in
cultured cells was observed as two distinct populations, exhibiting
that these markers are expressed at intermediate and high levels.
The hyperthermia treatment further enhanced CD86-, CD40-,
and MHCII-high expressing populations in immature and LPS
matured cultures. Not only the in vitro hyperthermia caused an up
regulation in maturation markers expression, it also enhanced the
kinetics of maturation in terms of CD40 expression. The immature
as well as LPS treated control groups show a peak of CD40
expression after 48 hours, whereas in the hyperthermia group, the
expression peaked within 36 hours (Figure S2).
The process of antigen presentation by dendritic cells requires
the migration of antigen carrying DCs from site of antigen
encounter to lymphoid organs, where these cells present the
processed antigens to lymphocytes. During this activation
associated migration process DC are known to down-regulate
the expression of CCR5 and up-regulate the expression of CCR7.
We also examined the effect of in vitro hyperthermia on the
expression of these migratory markers by flow cytometry. Results
are plotted in Figure 1. We observed a marked down-regulation in
expression of CCR5 in immature BMDCs and up regulation of
CCR7 in both maturing as well as immature cells, indicating that
hyperthermia alone is capable of inducing DC migration in
absence of any other maturation signal. These flow cytometry
results indicate that in vitro hyperthermia promotes the phenotypic
activation of DCs and also suggests its potential for enhancing
activation associated migration of DCs in vivo.
In vitro hyperthermia enhances T cell stimulatory
capacity of dendritic cells in allo MLR
The ability to prime naı ¨ve T cells is a critical function of
dendritc cells. Antigen pulsed DCs are known to elicit potent
antigen specific T helper responses in mice [22]. To examine the
functional maturation of BMDCs by hyperthermia, we compared
the T cell stimulatory capacity of in vitro hyperthermia treated
BMDCs (from Balb/c mice) to that of untreated BMDCs in an allo
MLR. As shown in Figure 2A, we found a significant (*) increase
(p=.0143) in the thymidine incorporation in cultures where
treated BMDCs were compared with untreated cells as stimulator
(0.1 M) cells to test their ability to stimulate responder (0.5 M)
lymph node cells from C57BL/6. A significant (**) increase
(p=0.0086) in proliferative capacity was also observed when we
used purified CD4+ T cells from spleen as responder cells (0.5 M).
Culture supernatant was also collected after 48 h and checked for
secretion of IFN-c, IL-4 and IL-17. Figure 2B shows that while in
vitro hyperthermia increased the secretion of both IFN-c and IL-
17, no detectable amount of IL-4 was secreted in the cultures. It is
to be noted that the cultures comprising of untreated DCs also
secretion IFN-c and IL-17 albeit at lower levels than cultures
comprising of treated samples. Also, no detectable IL-4 was
observed even in control cultures. This result verifies that in vitro
hyperthermia leads to maturation of BMDCs not only in terms of
phenotypic expression of maturation markers, but also functionally
in terms of their ability to stimulate T cells. These observations
suggest that the use of hyperthermia in vivo may lead to better
stimulation of T cells upon interacting with them in the lymphoid
organs.
In vitro hyperthermia enhances cytokine production by
dendritic cells
Upon antigen encounter and uptake, dendritic cells are known
to undergo maturation during which they secrete various
cytokines. The cytokine milieu in turn is an important factor
governing the type of immune response that will be generated. So
next, we studied the effect of in vitro hyperthermia on induction of
cytokine secretion by BMDCs. The cytokines secreted by DCs
contributes in determining the class of immune response by
providing suitable microenvironment to T cells. While the
production of IL-12 by DCs induces a type 1 pattern of cytokine
secretion by T cells, higher IL 10 is known to promote a Th2 kind
of Th cell response [23]. TNF-a is a plieotropic cytokine with
diverse functions in inflammation. Immature DCs are not known
to secrete these cytokines. As observed in Figure 3, while in vitro
hyperthermia alone did not lead to induction of cytokine secretion
by immature DCs, maturing DCs (matured by addition of LPS)
were found to secrete higher levels of IL-10 but lesser amount of
IL-12p70. The levels of TNF-a, however remained unchanged
(Figure 4).
Next, we performed further experiments to investigate if the
regulation of IL-12p70 and TNF-a secretion upon hyperthermia
exposure, depends on IL-10 secretion. Autocrine secretion of IL-
10 is known to affect the secretion of TNF-a as well as IL-12p70
due to its anti inflammatory property. To establish whether
treatment by in vitro hyperthermia is incapable of stimulating the
production of TNF-a and IL-12p70 and the observed decrease in
case of IL-12p70 is not due to autocrine secretion of large amounts
of IL-10, we performed neutralization experiment in which the IL-
10 secretion in DC cultures was neutralized using IL-10 mAb. We
found that the secretion of TNF-a and IL-12p40 remains
unaffected after IL-10 neutralization.
IL-12p70 is a hetero-dimer of IL-12 p40 and IL-12p35 subunits.
IL-10 secretion is known to down regulate with secretion of IL-
12p35. Therefore upon IL-10 neutralization, more of IL-12p35
may be produced and higher level of IL-12p70 was detected. But
this increase is independent of hyperthermia treatment as it was
observed in both control (37uC) and hyperthermia group for TNF-
a. Moreover the amount of IL-12p70 continues to be lesser in
hyperthermia group even after neutralization of IL-10, thus
establishing that in vitro hyperthermia indeed stimulates BMDCs
towards IL-10 secretion. This may be helpful in skewing the
immune response towards Th2 type.
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migration in draining lymph node
To determine the effect of local hyperthermia on dermal DC
maturation and migration to regional lymph node, we subjected
mice to in vivo local hyperthermia by placing the hyperthermia
inducing patch, containing either PBS or antigen, on the right
thigh of mice. After 24 hours, we prepared epidermal sheets from
treated area as well as untreated area of the mice skin and stained
them for CD11c+ cells. We observed a decrease in the number of
CD11c+ (Figure 5) cells in epidermal sheets taken from area of skin
where hyperthermia patch was placed, suggesting that short
duration hyperthermia indeed causes migration of DCs from skin
to lymph node.
To further verify this, skin DCs were fluorescently labelled in vivo
by the cutaneous injection of carboxyfluorescein diacetate
succinimidyl ester (CFSE) [24] and HET patch was placed at
the site of CFSE injection. We prepared the lymph node
suspensions after 24 hours of treatment, stained them with
CD11c-PE.Cy5 antibody. The population was gated for
CD11c+ cells on the basis of CD11c-PE.Cy5 staining and checked
Figure 1. In vitro hyperthermia differentially regulates the expression of maturation markers on BMDCs. Immature or LPS (1 mg/ml;
6 hours) matured BMDCs were either maintained at 37uC or exposed to hyperthermia for 42uC for 30 minutes and analyzed by flow cytometry at
indicated recovery periods, after staining with anti-CD80, anti-CD86, anti-MHC-II, anti-CD40, anti-CCR5 and anti-CCR7 mAbs. Results are shown as dot
plots indicating the percentage of cells expressing the various markers and are representative of three independent experiments.
doi:10.1371/journal.pone.0032067.g001
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migrated from skin. Figure 6 shows that HET treatment leads to
the enhanced migration of CD11c+ DCs from skin and the
migration is further enhanced when an antigen (TT in our case) is
incorporated in the HET patch.
We also performed similar experiment with animals immunized
by HET (along with TT antigen) and conventional needle
immunization. We found (Figure 7) that compared to control,
both HET groups (with or without antigen) showed a significant
increase in expression of Langerin marker, thus indicating that
mild hyperthermia of the HET patch is sufficient to cause an
enhanced migration of DCs from skin to draining lymph node.
To distinguish epidermal DCs (LCs) among the Langerin+
dermal DCs present in the lymph node, we utilized the selective
expression of cell adhesion molecule EpCAM on epidermal DCs
[25–28]. Figure 8 shows the dot plots of Langerin+ gated cells.
These data reinforce that heat alone leads to enhanced migration
of epidermal, EpCAM+ DCs to the draining lymph node. The
presence of an antigen (TT in our case) in the HET patch further
added to this enhancement. Further, the enhanced migration
remain localized to the nearest draining lymph node.
We further compared the HET immunization technique to
conventional needle immunization in terms of expression of
maturation markers on DCs in draining lymph node upon
immunization. Mice (n=3) were immunized by either conven-
tional intramuscular route or HET (with or without antigen).
Unimmunized animals served as control. As seen in Figure 9, the
expression of maturation marker on DCs of pooled draining
lymph node was higher in both groups of hyperthermia as
compared to needle immunization. Thus HET is not only superior
to needle immunization in this respect, but the effect also seems to
be independent of the presence of antigen, thus suggesting that
thermal component of HET immunization may be responsible for
this effect. This can be explained by our previous observation that
in-vitro hyperthermia is able to enhance the expression of
maturation and migration markers in BMDCs. Thus, the thermal
component of HET serves as an adjuvant in promoting the
maturation and migration of DCs to lymph node.
Priming by HET generates memory response
To evaluate the adjuvant effect of thermal component of HET
on final immune outcome in terms of antibody production and
recall response, we compared it with conventional alum adjuvant
during immunization. Mice (n=4) were immunized using soluble
TT (sTT), TT with alum or TT via HET. A group of
unimmunized mice (n=3) served as control where no primary
immunization was done. On day 28 after first immunization,
booster was given to all the groups via i/m injection of TT without
alum. One week later, the total serum IgG levels were estimated
by ELISA. As seen in the Figure 8 panel A3, an increase is seen in
total serum IgG levels in all immunization groups when compared
with control. Though the levels are lower in HET group compared
to sTT and TT with alum group, it is significantly higher than the
control group, thus establishing the ability of HET immunization
to generate a recall response. This is further established by the
proliferation assay. One week after the booster dose, the
proliferation response of cells from spleen were examined in
which re-stimulation was done with TT. The results are depicted
in Figure 10, panel B. The HET immunization led to the
generation of proliferative response which is not significantly
different (p=0.1480) from TT with alum group. Thus HET
immunization by TT is comparable to needle immunization for
primary antigen administration in terms of generation of recall
Figure 2. A. In vitro hyperthermia enhances the T cell proliferative capacity of BMDCs in allo MLR. BMDCs from Balb/c mice (stimulator;
0.1 M) were treated at 37uCo r4 2 uC for 30 minutes and co-cultured with either lymph node cells or purified CD 4+ T cells from spleen. B. Cytokines
secreted in supernatant of allo MLR as estimated by ELISA.
doi:10.1371/journal.pone.0032067.g002
Figure 3. In vitro hyperthermia affects the secretion of IL-10 by
BMDCs. Immature or LPS matured (1 mg/ml; 6 hour) BMDCs were
cultured at either 37uCo r4 2 uC for 30 minutes followed by recovery at
37uC. Supernatant were collected after 24 hours and cytokine levels
were determined by sandwich ELISA. Results are plotted as Mean 6SD
of a representative of three experiments.
doi:10.1371/journal.pone.0032067.g003
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hyperthermia. DCs were incubated at 37uC (light gray) or 42uC (dark gray) for 30 minutes, and allowed to recover at 37uC for 6 hours. Then 0.1 mg/
ml anti-IL-10 mAb or isotype control was added at the time of stimulation with 1 mg/ml LPS at 37uC for additional 22 hours. The supernatants were
collected and the concentrations of IL-12p70, IL-12p40 and TNF-a were measured by ELISA. Data are shown as Mean 6SD of one typical experiment
of three independent experiments.
doi:10.1371/journal.pone.0032067.g004
Figure 5. Migration of DCs from epidermis upon local Hyperthermia. Mice were given local hyperthermia by placing hyperthermia patched
on shaved skin. Epidermal sheets were prepared from control (A) and treated (B) mice 24 hours after treatments and stained for CD11c (PE). Nuclear
staining was done using DAPI. Images were taken at 106and are representative of three independent experiments.
doi:10.1371/journal.pone.0032067.g005
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thermal component of hyperthermia, we performed the subclass
analysis for serum IgG abs to TT, as the secretion of IgG1and
IgG2a isotypes of immunoglobulins is hallmark of Th2 and Th1
phenotypes of immune responses, respectively [29]. As shown in
the Figure 10, panel A1 and A2, while immunization with TT
without alum leads to generation of both IgG1 and IgG2a abs
suggesting a mixed Th response, the response generated in
presence of alum (TT with alum) or by HET was clearly skewed to
Th2 type with higher serum IgG1 compared to IgG2a.This
observation highlights that similar to the use of alum as adjuvant
[30], HET is also able to selectively potentiate a Th2 kind of
response. We have previously shown (Figure 3) that the thermal
component of HET stimulate the DCs to secrete IL-10 in vitro.I ti s
known that IL-10 play an important role in the Th2 response to
antigen [31], it thus provides a possible explanation for Th2 skew
during immunization by HET.
HET immunization protects mice against challenge
The success of any vaccine therapy depends on its ability to
confer protection against actual biological challenge. Thus to
determine the value of HET immunization as a novel transdermal
vaccine delivery technique, we wanted to evaluate its protective
efficacy. Since in our immunization experiments we found that
HET elicits lower IgG levels compared to convention i.m.
immunization, we followed multiple immunization regimen using
higher concentration of antigen (200 mg TT in the HET patch).
Mice (n=4) were immunized with 4 doses of TT via HET (Day 0,
Day 14, Day 28 and Day 42). Serum IgG levels were determined
one week after the last antigen dose and compared with single dose
HET immunization as well as i.m. needle immunization with TT
along with alum (single booster), as seen in Figure 11. One week
after the completion of immunization schedule, mice were
challenged with LD50 of biologically active toxin and observed
for a period of 5 days for mortality or paralysis. All animals in the
control group (unimmunized) were dead by the end of day 2. The
single dose of HET immunization was unable to provide sufficient
protection and all the animals were dead by the 4th day. In the
multiple HET immunization test group and conventional needle
immunization with one booster group, no death or paralysis was
observed and all the animals survived. The mice in the test group
did not show any symptoms of disease even after 2 weeks of
challenge, thus establishing the protective efficacy of vaccine
delivered through HET.
Discussion
The present study demonstrates that HET immunization is an
efficient way of needle free immunization generating a noticeable
serum antibody as well as recall response against the administered
antigen. Besides facilitating the passage of antigen across the skin,
the thermal component also induces the maturation and migration
of dendritic cells from the site of antigen application to the
draining lymph node. Moreover, similar to conventional adjuvants
like alum, HET also favours the development of IgG1 antibody
isotype upon recall, thus favouring a Th2 kind of immune
response.
The finding of this study that mild heat shock causes maturation
of DCs is in agreement with previously published reports [32–34].
Basu et al. [35] have investigated the effect of mild thermal stress
(up to 40uC) on the maturation of DCs and reported that the
duration of hyperthermia as well as the recovery at 37uC is critical
for the up regulation of maturation markers. On the contrary there
is report by Tournier et al. [36] which shows that thermal stimuli
for long durations of 3 hours with recovery period of 15 hours at
37uC had no effect on DC maturation. In the present study, we
have observed that hyperthermia at 42uC for a short duration of
Figure 6. Migration of carboxyfluorescein diacetate succinimidyl ester (CFSE) stained skin DCs to the lymph node. DCs were
fluorescently labelled in vivo by the cutaneous injection of CFSE (without HET) and in another experiments HET patch containing PBS or TT was
placed at the site of CFSE injection. After 24 h, cells from draining lymph nodes were stained with CD11c-PE.Cy5 antibody. Typical dot plots are
shown in which CD11c+ cells were gated and the CFSE+ cells were analyzed. Number on the selected area indicates percent of CFSE+ cells.
doi:10.1371/journal.pone.0032067.g006
Figure 7. Migration of LCs from epidermis upon local
Hyperthermia vs. needle immunization. Mice (n=3) were
immunized with TT by either conventional i/m (NI) or HET with
(H+TT) or without (H) antigen. Unimmunized animals served as control.
Cell suspension from draining lymph nodes were prepared after 24 h
and analyzed by flow cytometry after staining with Langerin (CD207)–
PE antibody. Results are expressed as % of positive cells in total draining
lymph node population.
doi:10.1371/journal.pone.0032067.g007
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markers. Moreover, the levels of MHC-II were found to be
elevated within 2 hours after treatment. While the co-stimulatory
molecules peaked at 24 hours of recovery, the migratory markers
showed maximum differential expression in 36 hours. This study
thus highlight that the optimum recovery period depends on the
marker maturation being investigated. This knowledge is critical to
observe the desirable effect of hyperthermia protocol being
investigated and should comprise an essential parameter of all
investigations in this field.
Mature DCs are the most potent APCs for stimulating naı ¨ve T
cells. Thus examining the T cell stimulatory capacity is
physiologically most significant feature for DC maturation. Our
observation that hyperthermia is able to enhance allo-stimulatory
T cell capacity is in agreement with other reports where the
enhancement in allo-stimulation at different combinations of
temperature and time for stimulation was investigated [33–36].
Besides up regulation of maturation markers, DC maturation is
accompanied by synthesis of inflammatory cytokines. Our
observation that hyperthermia alone does not induce cytokine
secretion by immature DCs is in accordance with previously
published work [36], but after the hyperthermia exposure at 42uC,
the DCs matured by LPS treatment show a cytokine profile which
is distinct from previous reports. While hyperthermia at temper-
atures up to 40uC is known to enhance secretion of pro-
inflammatory cytokine IL-12p70 and reduce the secretion of IL-
10 and TNF-a [36], upon treatment at 42uC in our study, we
found the down regulation in IL-12p70 and the level of IL-10 was
slightly elevated. The level of TNF-a remains unchanged. This
observation suggests that the mechanism underlying DC matura-
tion upon thermal stimulation may vary across the different
temperature ranges. Whereas the BMDCs maturation induced by
mild thermal stress have been reported to be independent of heat
shock associated transcription factor Hsf-1 [34,37], at tempera-
tures over 40uC heat shock proteins are usually induced which can
regulate cytokine expression by terminating general protein
synthesis or by inhibiting the transcription of cytokine genes.
Similar observations have also been reported on macrophages
[38]. Thus to accurately predict the outcome of thermal stimuli on
immune outcome, it is necessary to establish the mechanism by
which hyperthermia regulates DCs maturation across various
temperature ranges. This would comprise the most important area
of future research in hyperthermia mediated DC maturation.
Transcutaneous immunization is known to cause an enhanced
migration of skin dendritic cells from the topical site to the
draining lymph nodes [39,40]. Our results are also concurrent
with these observations, but unlike other published studies, we
have shown that the enhanced migration can be induced by
hyperthermia alone even in absence of antigen. We have
demonstrated in vivo that the hyperthermia causes activation
associated migration in skin dendritic cells. Furthermore, hyper-
thermia not only contributes to the enhanced migration of
Figure 8. Migration of EpCAM+ epidermal DCs to the lymph node. Mice were immunized by TT, with and without HET. Unimmunized (PBS
without HET) animals served as control. Cell suspension from draining and non-draining lymph nodes were prepared after 24 h and stained with
Langerin (CD207)-PE and EpCAM-Alexa Flour 488 antibodies. Stained cells were analyzed by flow cytometry, Langerin+ cells were gated and the
expression of EpCAM was analyzed. Number on the selected area indicates percent of EpCAM+ cells among Langerin+ cells in total lymph node cells.
The bar graph shows average percentages of three experiments.
doi:10.1371/journal.pone.0032067.g008
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peaking in 24 hours as compared to 2–4 days required by
conventional needle immunization (unpublished data). Thus the
thermal component of HET indeed plays an important role in
modulating the maturation and migration of skin DCs.
Secretion of IgG1 and IgG2a isotypes of immunoglobulins is
hallmark of Th2 and Th1 phenotypes of immune responses,
respectively [29]. Conventional adjuvants like alum show immune
modulatory function by promoting the production of IgG1 isotype,
thus promoting a Th2 kind of immune response [41]. We also
observed that upon giving a booster, the animals those received
TT by HET or conventional immunization along with alum
showed more of IgG1 kind of isotype whereas animals immunized
by soluble TT alone produced a mix response showing both IgG1
as well as IgG2a kind of serum isotypes. Thus the thermal
component of hyperthermia acts similar to the alum adjuvant by
promoting the production of Th2 isotype ultimately to produce the
Th2 skew.
The merits of using HET immunization are quite apparent in
being a painless, needle free delivery system. Moreover, since it has
significant immune modulatory potential, it will be interesting to
study this mode of immunization in context of poor immunogens
such as polysaccharides and haptens. But, the feasibility for its
clinical application will depend on the availability of a method for
accurate estimation of dose delivered, and currently we are
focusing on various strategies towards achieving this goal.
Materials and Methods
Ethics statement
All the procedures on animals were approved by the
Institutional Animal Ethics Committee of the National Institute
of Immunology, project serial number IAEC#/204/08.
Mice and immunization
BALB/c and C57BL/6 mice (The Jackson Laboratory, Bar
Harbor, ME), bred in the small animal facility of the National
Institute of Immunology, New Delhi, India were used in all
experiments. Mice were immunized intramuscularly with 2 mg/
animal of TT Ag (C.R.I., Kasauli) with or without alum 2 mg/
animal (Alhydrogel, Vedback, Denmark) in the needle immuni-
zation group. In the HET immunization group, 20 mg of soluble
antigen (in PBS)/animal was placed in the immunization patch at
42uC for 30 minutes as previously mentioned [11]. Briefly, for
HET immunization, mice were shaved on day -1 using cosmetic
grade hair removal cream and immunized on day 0 by placing
hyperthermia patch filled with 200 ml of antigen solution on the
shaved area for 30 minutes. Additional details on the HET
Figure 9. Immunization via intramuscular route and HET differentially affects the expression of MHC-II, CD 80 and CD 86 by DCs
from draining lymph nodes. Mice (n=3) were immunized with TT by either conventional i/m (NI) or HET with (H+TT) or without (H) antigen.
Unimmunized animals served as control. Cell suspension from draining lymph nodes were prepared on day 2 and analyzed by flow cytometry after
double staining with anti-CD 11c and anti-MHCII or anti-CD80 or anti-CD86. Results are expressed as % of double positive cells in total draining lymph
node population. These results are a representative of three independent experiments.
doi:10.1371/journal.pone.0032067.g009
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e32067Figure 10. Serum anti-TT Abs in mice primed by HET. Mice were immunized by soluble TT alone (i/m), TT with alum (i/m) or TT via HET.
Unimmunized animal served as control. Booster of soluble TT (i/m) was given on Day 28 and mice were bled on week 5. Serum anti TT IgG1 (A1),
IgG2a (A2) and IgG (A3) were estimated by ELISA. Recall response was evaluated by estimating the proliferative index by in vitro restimulation of
splenocytes from immunized animals with TT antigen (B). Each dot represents individual animal and bars represent the geometric mean of each
group.
doi:10.1371/journal.pone.0032067.g010
Figure 11. Boosting upon HET immunization and toxin challenge. Mice were immunized via a single dose of HET patch or multiple doses of
HET patch on day 0, 14, 28 and 42. The positive control was needle immunized with TT+alum on day 0 and 28. Toxin challenge was given one week
after the completion of immunization schedule.
doi:10.1371/journal.pone.0032067.g011
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from the retro-orbital venous plexus under ketamine/xylazine
anaesthesia and sera separated for Ab assays. For lymph node cells
activation markers expression, DCs migration, and measurement
of T cell responses, mice were euthanized by cervical dislocation
and spleens or lymph nodes were isolated and single cell
suspensions were prepared for use. Group sizes of 3–5 mice each
were used for the serologic experiments, while 3 mice each were
used for the T cell proliferation and activation and migration
analysis experiments.
Generation of bone marrow dendritic cells (BMDCs)
BMDCs were generated in vitro from bone marrow. Briefly,
femur and tibiae were removed from 8–10 weeks old Balb/c mice.
Intact bones were left in 70% ethanol for 1 minute for disinfection
and washed with PBS. Both the ends of bone were cut open under
sterile conditions, bone marrow cells were flushed out and washed
with RPMI1640 medium. Bone marrow cells (4610
6) were
cultured in 6 well plates at concentration of 10
6 cells/ml in RPMI
1640 (Biological Industries) medium supplemented with 10% heat
inactivated FBS (Biological Industries), 100 Units/ml penicillin,
100 mg/ml streptomycin, 250 mg/ml amphotericin B (Sigma) and
10 ng/ml murine rGM-CSF (Peprotech) at 37uC and 5%CO2.
On day 3 and 5, 75% of media was removed from each well and
3 ml of fresh media supplemented with 10 ng/ml GM-CSF was
added. On day 7, non adherent cells were harvested and used as
immature DCs. The immature DCs were given a hyperthermia
treatment at 42uC for 30 minutes followed by recovery at 37uC for
indicated time period. The control cells were maintained at 37uC
during this treatment period.
In vivo Local Hyperthermia and kinetics of DC migration,
antigen presenting and co-stimulatory activity in lymph
node
To determine the effect of local hyperthermia on the kinetics of
DC migration and MHCII and co-stimulatory molecule expres-
sion in lymph node, animals were subjected to 30 minutes of local
hyperthermia by placing the patch (PBS alone or PBS containing
antigen) on the right thigh of the animal. Inguinal lymph nodes
from the same side as well as laterally opposite side were isolated
after indicated time periods (24, 48 and 72 hours). Cells harvested
from the lymph node were examined for expression of Langerin,
EpCAM, MHCII, CD80, CD86, and CD11c markers by flow
cytometry.
For the in vivo staining of endogenous skin DCs, mice were given
cutaneous injection of CFSE (Molecular Probes), 80 mg/animal in
PBS at the shaved area of flank under anesthetic conditions. After
the 15 minutes of CFSE injection mice were subjected to HET
treatment.
Flow cytometry
For flow cytometry, cells (5610
5/well) were incubated with
1 mg/ml anti-mouse CD16/32 antibodies (BD biosciences) in the
blocking buffer (0.1% sodium azide +1%BSA in PBS) for
30 minutes at 4uC to block non specific binding to FccIII/II
receptor. After washing with 0.1% sodium azide +1% BSA in PBS,
cells were incubated with primary antibodies (in PBS with 1%
BSA) on ice for 1 hour. After washing three times, cells were
incubated with secondary antibodies on ice for 1 hour. Stained
cells were washed thrice before fixing with 4% paraformaldehyde
and stored at 4uC until analyzed. Samples were run on a BD LSR
flow cytometer and data were analyzed using WinMDI 2.8 or
Cyflogic 1.2.1 shareware. Anti-CD11C-FITC (eBiosciences), was
used as the surface marker of DCs and Biotinylated-MHC-II,
Biotinylated-CD80, and Biotinylated-CD86 (all from BD Biosci-
ences) were used as primary antibodies, whereas S-PE (BD-
Biosciences) was used as secondary antibody.
For the analysis of in vivo CFSE stained skin DCs in the lymph
node, cells obtained from the lymph node were stained with
CD11c-Biotin (BD-Biosciences) (S-PE.Cy5 (eBiosceince) as sec-
ondary Ab). Because the number of CFSE+ cells was very small,
we ‘gated in’ only the CD11c+ cells and examined the CFSE+
cells.
Biotin-EpCAM (eBiosceince) mAb - Streptavdin-Alexa Flour
488 (Invtrogen) and PE conjugated Langerin (CD207) (eBio-
sceince) mAb were used to distinguish epidermal DCs among
Langerin+ cells in the lymph node. Since the number of Langerin+
cells is very small (typically 0.5%) in the lymph node, it was
difficult to visualize minor variations in the number of double
positive (Langerin+, EpCAM+) cells among different groups in a
conventional dot plot. We thus ‘gated in’ only the Langerin+ cells
and selected the EpCAM+ cells.
Allogenic Mixed Lymphocyte Reaction (MLR)
To estimate the proliferative capacity of BMDCs, DCs were
cultured from Balb/c mice and exposed to in vitro hyperthermia.
DCs from the hyperthermia group and the control were then co-
cultured with total lymph node cells or magnetically purified
CD4+ cells from spleen of C57BL/6 mouse in the allo MLR to
determine their proliferative capacity by estimating the incorpo-
ration of tritiated thymidine in the proliferative cells. Briefly, the
DCs (stimulator) and lymph node cells or purified CD4 T cells
(responder) cells were co-cultured at stimulator: responder
concentrations of 1:5 in 96-well U bottom microtiter plates
(Costar-Corning). Tritiated thymidine (0.5 mCi/well) was added at
72 hours and plates were frozen after 18 hours of thymidine
addition. For measuring the incorporated radioactivity, plates
were harvested on printed filtermats (Wallac) by micro 96
harvester (Molecular Devices) and counts measured using b-
scintillation counter (Perkin Elmer).
IL10 neutralization
BMDCs harvested at Day 7 of the culture were plated at
concentration of 1 M cells/ml in a 24 well plate. For performing
IL 10 neutralization, DC were either kept at 37uC (control) or
exposed to 42uC (hyperthermia) for 30 minutes and allowed to
recover at 37uC for 6 hours. After the recovery, 0.2 mg/ml of
neutralizing antibody (Anti mouse IL 10, clone JES5-245,
eBiosciences) or isotype control were added. After 1 hour of
incubation with neutralizing antibodies, LPS was added at 1 mg/
ml concentration. Supernatant was collected after 22 hours of
culture and stored at 270uC till assay was performed.
Cytokine measurement in supernatants
Cytokine levels in supernatants were determined by using
commercial sandwich ELISA kits. IL-12p70 ELISA was per-
formed using eBiosciences kit whereas IL-10, IL-12 p40, and
TNF-a ELISA were performed using kit from BD Biosciences.
The ELISA reactions were developed using TMB substrate (BD
biosciences) and read at 450 nm.
Immunohistochemistry of skin
Balb/c mice were shaved using cosmetic grade hair removing
cream. Next day mice were given local hyperthermia. After defined
period of time, mice were euthanized and skin from the shaved area
was cut using scissors. The skin sample was then placed in ice cold
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any curling. The skin sample was then incubated at 4uC for
24 hours. Skin was then placed epidermal side down on a slide and
spread evenly to avoid any curling. It was incubated at 37uC for
1 minuteto allowtheepidermisto adhereto culture dish.Using fine
forceps, the dermis was gently lifted to allow only epidermis to stick.
The epidermis was fixed using 4% paraformaldehyde solution at
room temperature (25uC) for 30 minutes. It was then washed with
PBS. Blocking was done by 1% BSA in PBS for 30 minutes.
Primary antibody CD11c-biotin was added and incubated at room
temperature for 1 hour. The sample was washed three times with
PBS, followed by addition of streptavidin-PE. The sample was
further incubated at room temperature for 1 hour followed by three
washes with PBS. Sample was then incubated with DAPI for
5 minutes followed by three PBS washes. Finally the sample was
mounted using glycerol, covered with a cover slip and observed
under florescent microscope (Olympus IX 51) and images were
captured using DP controller software.
Ag-specific Ab assays
Antigen specific antibodies in immunized animal were detected
using indirect ELISA. Briefly, Maxisorp microtiter plates (Nunc)
were coated with the TT (1 mg/ml). Abs in immune sera were
detected by enzyme immunoassays using goat anti-mouse total
IgG (Sigma), IgG1 and IgG2a peroxidase (Serotec) followed by
TMB substrate solution (BD biosciences) and reaction was stopped
using 2N sulphuric acid. Optical density at 450 nm were observed
and used for comparing serum antibody levels.
Proliferation Assays
The memory response in the immunized animals was
determined using T cell proliferation assay. Briefly, one week
after the booster dose splenocytes were derived from animals in all
the groups. The splenocytes were then plated at concentration of
0.5 M cells/well in a 96 well cell culture plate, followed by
addition of 0.1 mg/well of TT. Tritiated thymidine was added
after 72 hours. After another 18 hours, plates were frozen at
270uC until the assay was performed.
Toxin challenge
Mice groups (n=4) injected s.c. 0.1 ml of different dilutions of
tetanus toxin (Indian Immunologicals, Hyderabad). Mice were
observed twice daily for 5 days for death/paralysis. LD50 was
defined as the dose at which at least 50% animals die/develop
paralysis by the end of 5 days and was determined to be 4.6 mg/
animal. Test and control mice (n=4) were challenged s.c. with
LD50. Mice were observed daily following challenge, and both
morbidity and mortality were recorded.
Statistical analysis
Statistical analysis was done using the two sided Student’s t-test.
Data are presented as mean 6 SD. The statistical analysis was
performed using Graph Pad Instat software (GraphPad Software
Inc. version 3.05).
Supporting Information
Figure S1 The confirmation of protocol for local hyperthermia.
Panel A shows the surgical implantation of the thermistor probe in
the mice and panel B depicts how the heating patch to generate
hyperthermia was placed over the skin. Panel C shows the
temperature profile generated upon treating the mice with local
hyperthermia at 42uC which confirms that the temperature
beneath skin immediately attains the desired temperature.
(TIF)
Figure S2 Kinetics of expression of CD40 on BMDCs.
Hyperthermia enhances the expression of CD 40 maturation
marker on DCs. BMDCs were given in-vitro hyperthermia (42uC,
30 minutes) with or without LPS maturation. In absences of
hyperthermia the expression of marker peaks after 48 hours
whereas upon hyperthermia stimulation, the peak appears at
36 hours of LPS stimulation.
(TIF)
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